Latest News

Deucravacitinib Demonstrates Sustained Efficacy and Safety in 4-Year Psoriasis Trial
Deucravacitinib Demonstrates Sustained Efficacy and Safety in 4-Year Psoriasis Trial

May 16th 2024

Bristol Myers Squibb announced 70% of patients maintained significant improvement after 4 years with no new safety concerns.

Reviewing a Year of Plaque Psoriasis Progress: Therapies, Data, and Education
Reviewing a Year of Plaque Psoriasis Progress: Therapies, Data, and Education

May 14th 2024

ICYMI: sBLA for Hyrimoz (Adalimumab-adaz) Approved as Interchangeable Biosimilar to Humira
ICYMI: sBLA for Hyrimoz (Adalimumab-adaz) Approved as Interchangeable Biosimilar to Humira

May 13th 2024

Inflammation May Play A Similar Role in Atopic Dermatitis, Psoriasis, And Major Depressive Disorder
Inflammation May Play A Similar Role in Atopic Dermatitis, Psoriasis, And Major Depressive Disorder

May 10th 2024

FDA Approves A High-Concentration, Citrate-Free Version of Cyltezo, A Biosimilar to Humira
FDA Approves A High-Concentration, Citrate-Free Version of Cyltezo, A Biosimilar to Humira

May 1st 2024

© 2024 MJH Life Sciences

All rights reserved.